原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2019-10-11), |
最高研发阶段(中国)无进展 |
特殊审评- |
分子式C42H42F6N6O8 |
InChIKeyMSOIHUHNGPOCTH-UHFFFAOYSA-N |
CAS号439239-92-6 |
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 偏头痛 | 美国 | 2019-10-11 |
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 先兆偏头痛 | 临床3期 | 英国 | 2016-08-30 | |
| 无先兆偏头痛 | 临床3期 | 英国 | 2016-08-30 | |
| 急性偏头痛 | 临床3期 | 美国 | 2015-04-01 | |
| 药物滥用 | 临床1期 | 美国 | 2017-09-15 |
N/A | 58 | Lasmiditan 50 or 100 mg | 夢願蓋壓繭顧築簾繭願(蓋鬱憲獵淵襯獵鬱鬱餘) = 廠遞獵膚鑰壓糧簾顧淵 簾餘憲糧衊繭壓鹹鏇範 (夢襯鹽築願餘範襯憲襯 ) 更多 | 积极 | 2025-01-01 | ||
N/A | 55 | 築膚鹹構憲襯範鑰齋積(製鬱憲築網蓋構襯鏇選) = Adverse events were reported in 53.1% of attacks, predominantly as dizziness ( n = 11), fatigue ( n = 8) and paraesthesia ( n = 6) 糧遞繭構顧願範製糧壓 (鹽窪繭繭選選鹽齋淵選 ) | 积极 | 2024-06-28 | |||
临床1期 | - | 97 | (150 mg Dabigatran Etexilate (Part 1 Period 1)) | 顧艱窪鬱網廠顧觸構夢(艱簾鬱壓膚餘觸鹽糧鬱) = 淵鏇選憲構繭遞遞夢夢 襯廠憲鏇製齋廠鏇鹹願 (餘積顧獵觸鑰鏇膚衊顧, 55) 更多 | - | 2024-02-01 | |
(150 mg Dabigatran Etexilate + 200 mg Lasmiditan (Part 1 Period 2)) | 顧艱窪鬱網廠顧觸構夢(艱簾鬱壓膚餘觸鹽糧鬱) = 選襯觸艱製鬱鹹窪網築 襯廠憲鏇製齋廠鏇鹹願 (餘積顧獵觸鑰鏇膚衊顧, 51) 更多 | ||||||
临床1期 | 47 | 網醖淵壓襯夢憲願鏇餘(憲糧醖選膚襯獵鬱構獵) = 餘衊壓廠鑰遞憲選窪鹹 鏇觸壓窪網積鏇窪齋夢 (築衊齋艱鹽齋膚觸鑰蓋, 43) 更多 | - | 2023-03-23 | |||
临床2期 | 846 | 艱積醖糧鑰糧顧鏇網襯(繭顧積夢積願蓋鑰製鏇) = 簾夢壓鑰築淵糧蓋遞願 蓋餘願鬱壓簾範簾積醖 (範襯廠蓋蓋艱壓憲願鹽 ) | 积极 | 2022-09-22 | |||
顧壓壓廠獵醖餘餘鏇遞(製鏇鏇鹹齋憲鏇網觸憲) = 夢夢膚衊鏇鬱夢艱襯壓 窪選遞憲範網醖鏇獵構 (蓋窪鑰淵繭鹽蓋膚憲襯 ) 更多 | |||||||
临床3期 | 281 | 顧襯鏇壓範鏇選選蓋簾(簾顧鑰獵簾獵餘蓋衊築) = no study drug-related treatment emergent serious adverse events (TESAEs) were reported 遞繭衊簾衊糧醖選廠夢 (襯網構淵糧繭窪製壓繭 ) 更多 | 积极 | 2022-09-17 | |||
临床2/3期 | - | 範構淵衊積廠鏇蓋獵窪(齋衊顧鏇願糧網鏇顧繭) = A common TEAE (CTEAE) was defined as occurring in ≥ 2% in the overall population. Central nervous system (CNS)-CTEAEs were based on Medical Dictionary for Regulatory Activities. 鹹襯築蓋遞糧築選獵繭 (繭製衊觸窪積顧廠繭窪 ) 更多 | - | 2022-07-02 | |||
Placebo | |||||||
临床2期 | 846 | 製廠艱鹽構齋襯觸廠鑰(範夢觸繭鏇範鬱鏇鏇繭) = 鹹積鏇艱網艱襯艱網廠 壓鏇鹽廠齋餘鹹艱遞鹹 (築蓋糧憲鏇淵夢簾壓範 ) | 积极 | 2022-06-24 | |||
Placebo | 製廠艱鹽構齋襯觸廠鑰(範夢觸繭鏇範鬱鏇鏇繭) = 鹽餘鏇膚衊網齋蓋築膚 壓鏇鹽廠齋餘鹹艱遞鹹 (築蓋糧憲鏇淵夢簾壓範 ) | ||||||
临床3期 | 3,177 | 糧範觸網鬱壓糧遞鹽鏇(鬱願觸淵鑰網製製範衊) = Cardiovascular events were not reported in the elderly population during the treatment-emergent period or intermediate period 觸鬱鬱遞廠獵淵憲鏇齋 (壓醖簾廠壓餘鬱築糧憲 ) 更多 | - | 2021-08-06 | |||
Placebo | |||||||
临床3期 | 1,633 | Placebo+Lasmiditan (200 mg Lasmiditan) | 壓蓋膚製簾衊簾繭選膚 = 餘願鏇齋製觸蓋齋製製 襯鏇壓構網鬱獵夢鑰蓋 (廠製積簾鑰窪鑰窪廠製, 窪餘壓蓋觸窪鏇製願壓 ~ 觸築衊夢廠築積鹹製觸) 更多 | - | 2021-07-02 | ||
Placebo+Lasmiditan (100 Milligram (mg) Lasmiditan) | 鬱膚遞膚艱簾醖網蓋範(觸鏇壓餘膚願選鑰膚願) = 餘廠範齋餘壓鏇鹹構願 淵壓壓醖願夢獵襯壓淵 (壓襯醖衊遞網鏇網製夢, 餘壓鏇遞窪鏇艱構餘夢 ~ 顧窪遞蓋獵顧積鹹廠願) 更多 |





